Parabilis Medicines Prices Upsized IPO at $20/Share, Raises $670M; Regeneron Buys $75M in Private Placement
Summary
Parabilis Medicines announced the pricing of its upsized initial public offering at $20.00 per share, raising gross proceeds of $670 million from the sale of 33.5 million shares. This follows earlier news of the company aiming to significantly increase its IPO size. Additionally, Regeneron Pharmaceuticals invested $75 million in a concurrent private placement, purchasing 4,166,666 shares at $18.00 per share. The combined capital raise of $745 million provides substantial funding for the clinical-stage biopharmaceutical company. The stock is expected to begin trading on the Nasdaq Global Select Market on June 10, 2026, under the ticker symbol "PBLS".
This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.